Title : Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.

Pub. Date : 2004 Sep-Oct

PMID : 15517875






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Enhanced apoptosis by the co-treatment was abrogated by ectopic expression of cyclin D1, c-Myc or active MEK CONCLUSION: The combination of FK228 with STI571 is a promising treatment for Bcr-Abl-positive CML, but the activation of the MEK/ERK pathway and its downstream target genes may bring resistance to the co-treatment in leukemic cells. Imatinib Mesylate MYC proto-oncogene, bHLH transcription factor Homo sapiens